Eli Lilly Unveils $700 Million R&D Center in Boston to Boost Genetic Medicine Efforts
Eli Lilly & Co. (NYSE: LLY) has inaugurated its new R&D center in Boston’s Seaport...
Eli Lilly
Eli Lilly & Co. Resolves Manufacturing Constraints, Reports 37% YOY Sales Growth in Q2 2024
Eli Lilly & Co. (NYSE: LLY), a prominent pharmaceutical company based in the U.S., has...
Eli Lilly’s Mounjaro Approved by China’s NMPA for Long-Term Weight Management
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the US, has announced...
Eli Lilly’s Lupus Treatment LY3361237 Misses Mark in Phase II Trial
Eli Lilly & Co. (NYSE: LLY) has encountered a setback in its drug development pipeline...
Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...
Lilly’s Kisunla Poised to Shake Up Alzheimer’s Treatment Market with FDA Approval
Eli Lilly & Co. (NYSE: LLY) has announced that the U.S. Food and Drug Administration...
Eli Lilly & Co. Strikes Deal for Radionetics’ GPCR-Targeted Radiopharmaceuticals
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the US, has...
Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious...
Eli Lilly & Co. Partners with OpenAI to Use Generative AI in Antimicrobial Drug Discovery
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company based in the U.S., has...
AbbVie Warns Shareholders Against Tutanota’s Unsolicited Mini-Tender Offer
Private investment firm Tutanota has launched an unsolicited mini-tender offer to acquire up to 250,000...
Eli Lilly’s Baqsimi Gains NMPA Approval for Diabetes Hypoglycemia Treatment
The National Medical Products Administration (NMPA) in China has granted approval to Eli Lilly &...
Eli Lilly’s Tirzepatide Hits Primary Endpoint in MASH Trial, Outperforming Placebo
Eli Lilly and Company (NYSE: LLY), a global healthcare conglomerate, has announced positive outcomes from...
FDA Committee Backs Eli Lilly’s Donanemab for Early Symptomatic Alzheimer’s Disease
This week, a US Food and Drug Administration (FDA) advisory committee endorsed the safety and...
Xtalpi Inc. Makes a Splash with HKD 1.13 Billion IPO on Hong Kong Stock Exchange
XtalPi (QuantumPharm, HKG: 2228) has successfully conducted an initial public offering (IPO) on the Hong...
Eli Lilly Acquires QurAlis’ UNC13A-Targeting Compounds for Neurodegenerative Diseases
Eli Lilly and Company (NYSE: LLY) has announced the acquisition of global development and commercialization...
Eli Lilly’s KRAS Inhibitor Olomorasib Shows Promise in Phase I/II Trial for Advanced Solid Tumors
Eli Lilly and Company (NYSE: LLY) has presented an update on a Phase I/II clinical...
Eli Lilly Launches New Formula of Taltz in China with Reduced Injection Site Pain
Eli Lilly and Company (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced...
Eli Lilly Invests $5.3 Billion to Expand Manufacturing Capacity for Incretin Receptor Agonists
Eli Lilly and Company (NYSE: LLY) has announced a significant investment of USD 5.3 billion...
Eli Lilly Partners with Aktis Oncology to Advance Cancer Radiopharmaceuticals
Eli Lilly and Company (NYSE: LLY) has announced a strategic partnership with Aktis Oncology, a...
Eli Lilly’s Tirzepatide Earns China Approval for Type 2 Diabetes Treatment
Eli Lilly & Co. (NYSE: LLY), a leading US pharmaceutical company, has announced that it...